Windtree Therapeutics, Inc.
WINT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | 0.00 | -0.00 |
| FCF Yield | -341,250.50% | -105,561.35% | -17,550.00% | -82.27% |
| EV / EBITDA | 0.00 | -0.80 | -0.10 | 1.63 |
| Quality | ||||
| ROIC | 0.00% | -16.32% | -19.16% | -24.43% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 50.00% |
| Cash Conversion Ratio | 0.23 | 0.25 | 0.60 | -1.33 |
| Growth | ||||
| Revenue 3-Year CAGR | 448,040.47% | 448,040.47% | 448,040.47% | 448,040.47% |
| Free Cash Flow Growth | -139.82% | -10.39% | 34.68% | 42.82% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | -0.80 | -0.10 | 0.02 |
| Interest Coverage | 0.00 | -50.43 | -204.50 | -90.84 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -21,827.65 | -16,464.71 | 0.00 |